Iluvien (Fluocinolone Acetonide)

Fluocinolone acetonide binds to glucocorticoid receptors inside ocular cells, modulating gene transcription. This suppresses inflammatory cytokines, prostaglandins, and other mediators, leading to reduced vascular permeability, decreased fluid leakage, and control of inflammatory processes within the retina and posterior segment.

Iluvien is supplied as a single‑use 0.19 mg intravitreal implant. The prescribing ophthalmologist determines the need for implantation and may consider re‑implantation after approximately 36 months, based on the patient’s response and disease activity.

The pregnancy category for fluocinolone acetonide intravitreal implants is unknown. Use is only recommended if the potential benefit justifies any possible risk to the fetus. Limited data exist for breastfeeding; the decision should be made in consultation with a healthcare professional.

To order Iluvien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

The main alternative intravitreal corticosteroid is the dexamethasone implant (Ozurdex), which releases drug over a shorter period and may require more frequent re‑injection. Anti‑VEGF agents are also used for diabetic macular edema but act on a different pathway. Iluvien provides a longer‑lasting release (up to 36 months), reducing the need for repeated procedures.

Iluvien should be stored below 25 °C in its original packaging. Protect the implant from moisture and direct light. Do not freeze or expose it to extreme temperatures, as this could compromise the sustained‑release matrix.

Iluvien is implanted by a qualified ophthalmic surgeon using a sterile intravitreal injection technique. The implant is placed into the vitreous cavity through a pars plana approach under local or topical anesthesia, typically in an outpatient setting.

Serious risks include elevated intra‑ocular pressure that may lead to glaucoma, cataract formation, endophthalmitis (intra‑ocular infection), retinal detachment, and rare cases of implant migration. Patients should be monitored regularly for these complications, and any signs of infection or vision loss require immediate medical attention.

Iluvien is contraindicated in patients with active ocular infection, known hypersensitivity to fluocinolone acetonide or implant components, uncontrolled glaucoma, or those who cannot undergo intravitreal surgery. Caution is also advised for individuals with a history of severe steroid‑induced intra‑ocular pressure spikes.